Future Directions in Pain Management: Integrating Anatomically Selective Delivery Techniques with Novel Molecularly Selective Agents

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Treatment for chronic, locoregional pain ranks among the most prevalent unmet medical needs. The failure of systemic analgesic drugs, such as opioids, is often due to their off-target toxicity, development of tolerance, and abuse potential. Interventional pain procedures provide target specificity but lack pharmacologically selective agents with long-term efficacy. Gene therapy vectors are a new tool for the development of molecularly selective pain therapies, which have already been proved to provide durable analgesia in preclinical models. Taken together, advances in image-guided delivery and gene therapy may lead to a new class of dual selective analgesic treatments integrating the molecular selectivity of analgesic genes with the anatomic selectivity of interventional delivery techniques.

Original languageEnglish (US)
Pages (from-to)522-533
Number of pages12
JournalMayo Clinic Proceedings
Volume91
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Pain Management
Analgesics
Genetic Therapy
Pain
Chronic Pain
Analgesia
Opioid Analgesics
Therapeutics
Genes
Direction compound

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{3c8957ceefe74e198632d36743cdb1cc,
title = "Future Directions in Pain Management: Integrating Anatomically Selective Delivery Techniques with Novel Molecularly Selective Agents",
abstract = "Treatment for chronic, locoregional pain ranks among the most prevalent unmet medical needs. The failure of systemic analgesic drugs, such as opioids, is often due to their off-target toxicity, development of tolerance, and abuse potential. Interventional pain procedures provide target specificity but lack pharmacologically selective agents with long-term efficacy. Gene therapy vectors are a new tool for the development of molecularly selective pain therapies, which have already been proved to provide durable analgesia in preclinical models. Taken together, advances in image-guided delivery and gene therapy may lead to a new class of dual selective analgesic treatments integrating the molecular selectivity of analgesic genes with the anatomic selectivity of interventional delivery techniques.",
author = "Josef Pleticha and Timothy Maus and Beutler, {Andreas S}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.mayocp.2016.02.015",
language = "English (US)",
volume = "91",
pages = "522--533",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "4",

}

TY - JOUR

T1 - Future Directions in Pain Management

T2 - Integrating Anatomically Selective Delivery Techniques with Novel Molecularly Selective Agents

AU - Pleticha, Josef

AU - Maus, Timothy

AU - Beutler, Andreas S

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Treatment for chronic, locoregional pain ranks among the most prevalent unmet medical needs. The failure of systemic analgesic drugs, such as opioids, is often due to their off-target toxicity, development of tolerance, and abuse potential. Interventional pain procedures provide target specificity but lack pharmacologically selective agents with long-term efficacy. Gene therapy vectors are a new tool for the development of molecularly selective pain therapies, which have already been proved to provide durable analgesia in preclinical models. Taken together, advances in image-guided delivery and gene therapy may lead to a new class of dual selective analgesic treatments integrating the molecular selectivity of analgesic genes with the anatomic selectivity of interventional delivery techniques.

AB - Treatment for chronic, locoregional pain ranks among the most prevalent unmet medical needs. The failure of systemic analgesic drugs, such as opioids, is often due to their off-target toxicity, development of tolerance, and abuse potential. Interventional pain procedures provide target specificity but lack pharmacologically selective agents with long-term efficacy. Gene therapy vectors are a new tool for the development of molecularly selective pain therapies, which have already been proved to provide durable analgesia in preclinical models. Taken together, advances in image-guided delivery and gene therapy may lead to a new class of dual selective analgesic treatments integrating the molecular selectivity of analgesic genes with the anatomic selectivity of interventional delivery techniques.

UR - http://www.scopus.com/inward/record.url?scp=84962339999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962339999&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2016.02.015

DO - 10.1016/j.mayocp.2016.02.015

M3 - Article

C2 - 27046525

AN - SCOPUS:84962339999

VL - 91

SP - 522

EP - 533

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 4

ER -